211MO Giredestrant (GDC-9545) vs physician choice of endocrine monotherapy (PCET) in patients (pts) with ER+, HER2– locally advanced/metastatic breast cancer (LA/mBC): Primary analysis of the phase II, randomised, open-label acelERA BC study

M. Martín Jiménez, Elgene Lim, M. Chavez Mac Gregor, Amit Bardia, Jun Wu, Q. Zhang, Zbigniew Nowecki, F. Melo Cruz, Р. Р. Сафин, S-B. Kim, Christian Schem, Alberto J. Montero, Simran Khan, R. Bandyopadhyay, Mahesh Shivhare, Monika Patre, Jorge Martinalbo, Laura Roncoroni, P.D. Pérez-Moreno, Joohyuk Sohn